| Product Candidate | Indication | Clinical Status | Partner/Licensee |
|---|
Ipilimumab
anti-CTLA4 |
Melanoma, Prostate Cancer, Lung Cancer and Others |
Phase 3 and earlier |
Wholly-owned |
MDX-1100
anti-IP10 |
Ulcerative Colitis, Rheumatoid Arthritis |
Phase 2 |
Wholly-owned
|
MEDI-545 and MEDI-546
anti-IFNα Pathway |
Lupus and Autoimmune Diseases |
Phase 2 and earlier |
MedImmune/AstraZeneca
Co-promote option |
MDX-1342
anti-CD19 |
Chronic Lymphocytic Leukemia, Rheumatoid Arthritis |
Phase 1 |
Wholly-owned
|
MDX-1106 (ONO-4538)
anti-PD1 |
Cancer, Hepatitis C |
Phase 1 |
Ono Pharmaceutical
Co-development |
MDX-1105
anti-PD-L1 |
Cancer |
Phase 1 |
Wholly-owned
|
MDX-1401
anti-CD30 |
Hodgkin Lymphoma |
Phase 1 |
Wholly-owned
|
MDX-1411
anti-CD70 |
Cancer |
Phase 1 |
Wholly-owned
|
MDX-1203
anti-CD70 Antibody-Drug Conjugate |
Cancer |
Phase 1 |
Wholly-owned
|
ValortimTM (MDX-1303)
anti-B. anthracis PA |
Anthrax Infection |
Phase 1 |
PharmAthene
Co-development |
| Product Candidate | Indication | Clinical Status | Partner/Licensee |
|---|
STELARATM (ustekinumab)
anti-IL12/IL23 |
Psoriasis |
Approved in Canada and Europe |
Centocor Ortho Biotech
Milestones/Royalties |
SIMPONITM (golimumab)
anti-TNFα |
Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis |
Approved in Canada and U.S. |
Centocor Ortho Biotech
Milestones/Royalties |
Ilaris® (canakinumab)
anti-IL1β |
Cryopirin-associated Periodic Syndromes |
Approved in U.S. |
Novartis Pharma
Milestones/Royalties |
Ofatumumab (HuMax-CD20)
anti-CD20 |
Chronic Lymphocytic Leukemia, Rheumatoid Arthritis |
BLA/MAA Filed |
Genmab/GlaxoSmithKline
Equity Interest |
Zalutumumab (HuMax-EGFR)
anti-EGFR |
Head and Neck Cancer |
Phase 3 |
Genmab
Equity Interest |
MDX-066 (CDA-1) +
MDX-1388 (CDA-2)
anti-C. difficile Toxin A and Toxin B |
C. difficile Infection |
Phase 2 |
Merck & Co.
Co-development* |
* All payments divided equally between Medarex and co-development partner, MBL.
